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Background 
There is considerable concern that chemical
exposures are contributing to the increasing
incidence of neurodevelopmental diseases in
children (Schettler 2001). However, most
chemicals have not been evaluated for their
potential to cause developmental neurotoxic-
ity (Goldman and Koduru 2000). To fill this
information gap, industry is increasingly
being asked to provide adequate information
for the assessment of developmental neuro-
toxicity in its products and wastes. In
response, developmental neurotoxicity testing
(DNT) needs are expected to increase signifi-
cantly in the United States and globally.
Current DNT testing guidelines, U.S.
Environmental Protection Agency (EPA)
870.6300 DNT Guideline (U.S. EPA 1998)
and the draft OECD 426 [Organisation for
Economic Co-operation and Development
(OECD) 2006] are expensive in terms of sci-
entific resources, time, money, and animals
(Lein et al. 2005), and risk-based criteria for
setting testing priorities have yet to be devel-
oped. Relying solely on the existing guide-
lines to address current and anticipated future
regulatory demands for DNT of the thou-
sands of chemicals for which there is little to
no DNT data would incur unacceptable costs
in terms of animals and person-years. There is
also increasing pressure on the scientific and
regulatory communities from environmental
health and children’s welfare advocacy groups
to test more chemicals for their potential to
harm the developing human nervous system.
Thus, there is strong incentive to create alter-
native methodologies that meet the expressed
demands for identifying potential develop-
mental neurotoxic agents with speed, reliabil-
ity, and respect for animal welfare. 
The Johns Hopkins Center for Alternatives
to Animal Testing (CAAT) introduced its first
TestSmart program in 1999 to develop a more
humane and efficient approach to risk assess-
ment of high production volume (HPV) chem-
icals. The TestSmart process brings together
diverse stakeholder groups from around the
world, including research scientists, govern-
ment scientists, regulators, policy analysts,
industry representatives, academics, and public
interest groups, encouraging them to work col-
laboratively so that as the science is developed,
its policy implications will be understood, and,
as policy needs are articulated, the science can
respond. After the TestSmart HPV workshop
(26–27 April 1999, Fairfax, VA, the U.S. EPA
announced it had decreased its estimates for
animal use by 80%. This estimate was based
partly on the TestSmart HPV recommendation
that the OECD combine required assays and,
where possible, replace in vivo tests with
in vitro OECD assays. These data are available
from this website: http://caat.jhsph.edu/
programs/workshops/testsmart/index.htm
(CAAT 2007). Building on the success of this
program, CAAT is collaborating with the U.S.
EPA and the National Toxicology Program
(NTP) to adapt the TestSmart approach to
DNT. The goals of TestSmart DNT are to a)
identify alternative DNT models based on
evolutionarily conserved neurodevelopmental
end points of mechanistic relevance to devel-
opmental neurotoxicity; b) develop the process
for validating candidate alternative methods
both scientifically and in terms of regulatory
acceptance; and c) identify opportunities for
reducing, refining, or replacing the use of ani-
mals in DNT. These goals were derived in part
from a workshop sponsored by the CAAT, the
European Chemical Industry Council (Cefic),
and the European Center for the Validation of
Alternative Methods (ECVAM) in April 2005
in Ispra, Italy, which examined the current sta-
tus of alternatives for DNT testing. A report of
this workshop (Coecke et al. 2007) has been
published online by Environmental Health
Perspectives. 
Workshop Objectives
The primary objective of the first interna-
tional meeting of TestSmart DNT was to
bring together the various stakeholders (test
developers, test users, regulators and advo-
cates for children’s health, animal welfare and
environmental health) and individuals repre-
senting diverse disciplines (developmental
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Developmental neurotoxicity testing (DNT) is perceived by many stakeholders to be an area in
critical need of alternatives to current animal testing protocols and guidelines. To address this
need, the Johns Hopkins Center for Alternatives to Animal Testing (CAAT), the U.S.
Environmental Protection Agency, and the National Toxicology Program are collaborating in a
program called TestSmart DNT, the goals of which are to: (a) develop alternative methodologies
for identifying and prioritizing chemicals and exposures that may cause developmental neurotoxic-
ity in humans; (b) develop the policies for incorporating DNT alternatives into regulatory decision
making; and (c) identify opportunities for reducing, refining, or replacing the use of animals in
DNT. The first TestSmart DNT workshop was an open registration meeting held 13–15 March
2006 in Reston, Virginia. The primary objective was to bring together stakeholders (test develop-
ers, test users, regulators, and advocates for children’s health, animal welfare, and environmental
health) and individuals representing diverse disciplines (developmental neurobiology, toxicology,
policy, and regulatory science) from around the world to share information and concerns relating
to the science and policy of DNT. Individual presentations are available at the CAAT TestSmart
website. This report provides a synthesis of workgroup discussions and recommendations for
future directions and priorities, which include initiating a systematic evaluation of alternative
models and technologies, developing a framework for the creation of an open database to catalog
DNT data, and devising a strategy for harmonizing the validation process across international
jurisdictional borders. Key words: alternatives, developmental neurotoxicity testing, humane sci-
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neurobiology, toxicology, policy and regulatory
science) to exchange information and con-
cerns relating to DNT science and policy.
Additionally, the workshop sought to: (a) out-
line the opportunities for and challenges of
DNT alternatives; (b) initiate dialogue on pol-
icy requirements for validating candidate alter-
natives; (c) discuss the 3Rs (refining, reducing,
and replacing the use of animals) as they apply
to DNT; (d) establish a community of scientists
and policy makers who will work together to
integrate and coordinate the science and policy
of alternative DNT as it evolves; and (e) set the
agenda for the second TestSmart DNT meet-
ing (12–14 November 2006, Reston, VA). 
Workshop Summary:
Challenges and Opportunities
The science of DNT. Strategic approach to
developing DNT alternatives. A fundamental
scientific principle that has driven the success-
ful development of alternatives for toxicity test-
ing in organ systems is that highly conserved
events in the biology of a system or a process
provide a robust source of new efficient meth-
ods in target organ testing (Lein et al. 2005).
For example, the predictive power of in vitro
mutagenesis tests as screens for genotoxic
agents results from their incorporation of a rel-
evant biologic mechanism (DNA mutation)
that is conserved across species. Applying this
principle to developing alternatives for DNT is
challenging because the molecular mecha-
nism(s) by which developmental neurotoxi-
cants perturb neurodevelopment are not well
characterized. Moreover, because of the com-
plexity of the developing brain, it is likely that
there are many molecular mechanisms of
developmental neurotoxicity, a conclusion
borne out by mechanistic studies of neurode-
velopmental diseases. However, significant
advances in our understanding of the cellular
and molecular mechanisms of neurodevelop-
ment over the past 10 years have identified and
characterized key cellular events that are critical
to the formation of a functional nervous sys-
tem. These include neural induction, precursor
cell proliferation, pattern formation, cell migra-
tion, neuronal and glial differentiation, forma-
tion of axons and dendrites, axonal guidance
and target recognition, cell survival and apop-
tosis, synapse formation and pruning, and neu-
rotransmitter specification. It is now clear that
the fundamental principles underlying these
cellular events of neurodevelopment are
remarkably conserved across species ranging
from the nematode (Caenorhabditis elegans) to
human. These advances provide the opportu-
nity to develop DNT alternatives focused on
end points that capture key evolutionarily con-
served neurodevelopmental events. This strat-
egy is based on the prevailing thought in the
field that many developmental neurotoxicants,
regardless of their actual mechanism of action,
share common final outcomes of altered cell
proliferation and survival, aberrant cell differ-
entiation, or disrupted neuronal connectivity
(Barone et al. 2000; Lein et al. 2005; Slotkin
2004). The relevance of these end points to
developmental neurotoxicity is further sup-
ported by clinical studies of children and
experimental studies in primates, rodents, and
simpler organisms, indicating that perturbation
of these key neurodevelopmental events under-
lies functional deficits associated with neurode-
velopmental diseases of environmental and/or
genetic origin (Rice and Barone 2000). 
In vitro models and DNT. In vitro cell-
based models that recapitulate each of the
neurodevelopmental events listed above have
been developed to examine cellular and molec-
ular mechanisms of neurodevelopment. These
models, listed in order of increasing complex-
ity, include neurotypic and gliotypic cell lines,
primary neuronal and/or glial cell cultures,
reaggregate brain cultures, brain slices, and
organotypic explants. End points that can be
measured in these models include cellular
morphology, biochemical markers, neuro-
transmission, and molecular events (e.g., gene
expression and intracellular signaling). There
is considerable ongoing effort to develop the
technology for high(er) throughput/high(er)
content analyses of these end points. More
complex in vitro models, such as brain slices,
have also been adapted to study functional
correlates of complex behaviors, such as long-
term potentiation and synaptic plasticity.
Most of the primary cell culture models use
tissues from avian or rodent sources; however,
of particular interest to DNT is the availability
of human embryonic stem cells for culture.
Human neural progenitor cells, human stem
cell lines, and human cord blood–derived
stem cell models recapitulate several key neu-
rodevelopmental events, including differentia-
tion of precursor cells into neurons and glia
and the formation of neural networks. These
models could potentially reduce uncertainty in
cross-species extrapolation. 
The major advantage of in vitro cell-based
models is the ability to replicate discrete stages
of neurodevelopment in a relatively simple sys-
tem amenable to monitoring and manipula-
tion of gene expression. Because these models
reduce the complexity of the developing ner-
vous system, it is easier to detect subtle but
functionally important changes in cell prolifer-
ation and differentiation and neuronal connec-
tivity that are not easily observed in rodent
models. The availability of technology to mon-
itor or experimentally manipulate gene expres-
sion provides the opportunity to integrate
molecular data with structural and functional
observations at the cellular level and allows
adaptation of models to incorporate genetic
polymorphisms known or suspected to influ-
ence human susceptibility to developmental
neurotoxicants. However, adapting in vitro
cell-based models for DNT also poses signifi-
cant challenges. Because developmental neuro-
toxicity is contextually driven—neurotoxic
effects vary depending on brain region, devel-
opmental stage, and genetic background—the
use of these models raises concerns about miss-
ing critical cell–cell or gene–environment
interactions as well as differences between brain
regions and between developmental stages
(Lein et al. 2005). Another limitation of
in vitro cell-based models is the lack of inte-
grated systemic functions, which increases the
probability of missing toxicant effects on extra-
neural factors that influence neurodevelop-
ment, such as metabolism, immune mediators,
and endocrine function.
Alternative systems-based models and
DNT. The complexity of interdependent
events in the developing nervous system raises
concerns as to whether a DNT test battery
based on a few well-defined end points repro-
duced in vitro using cell-based models will be
predictive of in vivo effects. Therefore, systems-
based models employing simple organisms that
enable assessment of integrative effects may
offer a more immediately viable and ultimately
more powerful approach to DNT alternatives.
Simple organisms that have been proposed as
candidate DNT alternatives include (listed in
order of increasing evolutionary complexity)
sea urchins, nematodes (C. elegans), flies
(Drosophila melanogaster), fish [zebrafish
(Danio rerio) and medaka (Oryzias latipes)],
and chick embryos. Of these, C. elegans,
Drosophila, zebrafish, and chick embryos have
been used most extensively in mechanistic
studies of developmental neurobiology and
there exists a significant knowledge base
regarding cellular and molecular regulation of
neurodevelopment in these organisms. Such
studies demonstrate that although there are
notable differences between neurodevelopment
in these simpler organisms and mammals, the
fundamental processes of neurodevelopment
are analogous to those that occur in humans.
Moreover, genes homologous to human genes
linked to neurodevelopmental diseases are
expressed in these models. The complete
genome has been sequenced for C. elegans,
Drosophila, zebrafish, and medaka, the technol-
ogy is in place to monitor and experimentally
manipulate gene expression in nematodes, flies,
fish, and chick embryos, and some behavioral
tests have been developed for these models.
Thus, tools are available to integrate devel-
opmental neurotoxicity studies at the bio-
chemical, molecular, and cellular level with
alterations in structure, function, and behavior.
This will allow direct testing of cause–effect
relationships between toxicant effects on bio-
chemical, cellular, or molecular end points and
effects on apical measures such as behavior. In
addition, this information could be used to
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construct a genomics/proteomics database for
predicting developmental neurotoxic potential
across species at the most fundamental level of
homology. Ongoing studies are focused on
developing the technology to adapt these sys-
tems-based in vivo models for high(er)
throughput/high(er) content analyses of
genomic, proteomic, structural, biochemical,
and behavioral end points. 
A significant advantage of all these organ-
isms is their small size, rapid embryonic
development, and short life cycle, which will
greatly reduce time and space costs. Zebrafish
and medaka offer an advantage relative to the
other models in that their embryos are opti-
cally transparent. Thus, it is possible to visual-
ize dynamic changes in gene expression (using
fluorescent reporter transgenic lines) and
detailed morphogenetic movements as they
occur in the live developing embryo. This
provides the opportunity to study compen-
satory mechanisms in developing nervous sys-
tems exposed to neurotoxicants, and to obtain
repeated measures in the same organism over
time, thereby reducing the number of animals
required for testing. A major challenge con-
fronting all in vivo systems-based DNT alter-
natives is determining the impact of potential
species-specific toxicokinetic and toxicody-
namic differences. How similar are xenobiotic
metabolism and cellular defense mechanisms
in these organisms to those of humans?
However, the technology exists to “human-
ize” these organisms by stably expressing
human genes (e.g., metabolic enzymes), so it
may be possible to mitigate this problem. 
Challenges to the development and appli-
cation of DNT alternatives. Overall, a major
challenge, which is driven by limited resources,
is determining which of these in vitro cell-
based and in vivo systems-based models to fur-
ther develop as DNT alternatives. One
approach is to evaluate each model against a set
of characteristics defining the “ideal” DNT
alternative. Although these defining character-
istics require further discussion and refinement,
it is widely accepted that the most important
characteristic is that the model is predictive of
neurotoxic responses in the developing human
nervous system. Employing the strategy dis-
cussed above, alternative models for DNT
would be based on conserved mechanisms of
neurodevelopment. Additional characteristics
of an ideal DNT alternative include sensitivity,
specificity, and adaptability to high through-
put/high content analyses. Other, more prac-
tical concerns are that the test be rapid,
economical, and relatively simple to perform.
These practical concerns are readily addressed
for most candidate DNT alternatives, and
there is considerable work ongoing to adapt
many of these in vitro cell-based and in vivo
systems-based models for high(er) through-
put/high(er) content analyses. However, in
general, there is insufficient data to rigorously
evaluate the predictive validity, specificity or
sensitivity of either in vitro cell-based or
in vivo systems-based DNT alternatives. An
immediate need, therefore, is to begin testing
candidate models, ideally using a common set
of mechanistically diverse developmental neu-
rotoxicants to facilitate comparisons between
models. Generating a reference set of chemi-
cals to be used for testing alternative DNT
models is another issue demanding immediate
attention. An additional consideration is
establishing the criteria for assembling a bat-
tery of alternative DNT models. For example,
what types of data do regulators need, and
what model characteristics are required to
generate those data? 
A second major challenge is coordinating
the collection, storage, and analyses of DNT
data. Ideally, all stakeholders would openly
share information regarding alternative DNT
model development and testing in a public
database. Several issues will need to be
addressed to achieve this goal, not least of
which is identifying the resources to create and
maintain a database. Also relevant to this chal-
lenge is determining how best to apply com-
putational toxicology and systems biology to
integrate structural and functional data with
genomic, proteomic, and metabonomic data. 
The resources and effort required to tackle
these challenges are justified by the opportu-
nity for these DNT alternatives to increase the
rate of data acquisition while reducing the ani-
mal and other costs of DNT, thereby enhanc-
ing the ultimate goal of protecting children’s
health. Data obtained from either in vitro cell-
based or in vivo systems-based DNT alterna-
tives may provide insights into relevant cellular,
molecular, and regional targets, informing
mode-of-action hypotheses and identifying
potentially vulnerable developmental stages,
thereby refining and reducing mammalian
in vivo testing. A short-term goal is to identify
DNT alternatives that can be used to prioritize
chemicals for further testing, thereby focusing
resources on those chemicals most likely to be
hazardous to the developing nervous system.
Long term, these alternative DNT models have
the potential to replace at least some mam-
malian in vivo testing. 
Scientific and regulatory validation of
alternative DNT models. The interface
between developing science and its application
to policy can be understood most effectively by
discussing validation and regulatory accep-
tance. These concepts bridge the worlds of test
development, laboratory research, and applica-
tion of new test methods in regulation. A
robust, timely, internationally harmonized,
and effective path to validation and regulatory
acceptance is essential for the successful deploy-
ment of alternatives in developmental neuro-
toxicology (Spielmann and Liebsch 2002).
Validation: the process. Validation is the
process by which the reliability and relevance
of a test are established for a particular pur-
pose. In the context of validation, “reliability”
refers to the inter- and intralaboratory repro-
ducibility of a methodology [Garthoff 2005;
Interagency Coordinating Committee for
the Validation of Alternative Methods
(ICCVAM) 1997; Zeigler and Stokes 1998]
whereas “relevance” refers to a test’s ability to
measure, predict, or model a toxicologic event
of interest (Zeigler and Stokes 1998). In
many cases, an alternative test is judged to be
relevant if it produces information and data
that are equivalent to or better than the infor-
mation or data produced by a currently used
in vivo test. Simply put, the benchmark
for alternative tests is whether they are
deemed to be as predictive as (or more predic-
tive than) the tests they are intended to
replace (Spielmann and Liebsch 2002). 
Although the concept of validation is rela-
tively easy to define and describe, in practice
it remains challenging to implement for any
single test. The process of validation is deter-
mined by a variety of factors including: a) the
“comfort level” of the individual agencies or
organizations that evaluate the test, which is a
function of their statutory and regulatory
mandate (Zeigler and Stokes 1998); b) influ-
ence from pressure groups (Garthoff 2005);
and c) the perceived need for a new test pro-
tocol. Validation has evolved and improved in
the past 15 years. Early lessons, arising out of
the first unsuccessful attempts to validate
alternative tests to replace the Draize eye pro-
cedure (Spielmann and Liebsch 2001), led to
success in validating a number of tests, and
has witnessed their acceptance by ICCVAM,
ECVAM, and other international bodies,
such as the OECD. 
Validation: challenges and opportunities.
Despite these successes, test validation
remains challenging. First, it is very expensive
(Spielmann 2003). Second, it is time consum-
ing, taking 1.5–10 years (Garthoff 2005).
Third, validation can require the use of large
numbers of animals. Fourth, it can be difficult
to find a sponsor or group of sponsors for the
test (Spielmann and Liebsch 2002). Finally, as
we discuss below, validation in and of itself
offers no guarantee (at least in the United
States) that the data generated by an alterna-
tive test will be accepted for use in decision
making by a regulatory body (ICCVAM
1997; Zeigler and Stokes 1998). A specific
challenge facing DNT alternatives is that pre-
dictive validity is harder to conceptualize in
cases where correlative in vivo tests have not
been established. Biostatistians and modelers
can play an important role, and test developers
should strongly consider developing predictive
models based on statistics and systems biology
(Spielmann and Liebsch 2002).
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The presentations and discussions of the
first TestSmart DNT workshop support the
proposal that DNT alternatives, appropriately
developed, can yield valuable data for decision
making (Lein et al. 2005). The rate of
throughput is another potential advantage of
DNT alternatives over traditional in vivo
tests. Alternatives that simultaneously test
multiple end points of interest or multiple
compounds would rapidly expand the knowl-
edge base of developmental neurotoxicity.
Successful use of these alternatives in decision
making will require sorting them according to
their long-, medium-, or short-term potential. 
Regulatory acceptance: the process.
Validation of an alternative test is a necessary
but not the only step in using the test to make
decisions that will affect regulations (Garthoff
2005). Once validated, a test must pass
through another process to gain acceptance by
regulatory agencies in the United States, the
European Union, its member countries, and
other jurisdictions. Regulatory acceptance is
largely an ad hoc process that varies depending
on a) the agencies and jurisdictions involved
[e.g., the Centre for the Documentation and
Evaluation of Alternative Methods to Animal
Experiments (ZEBET) vs. OECD vs. U.S.
EPA]; b) the particular law or regulation for
which the testing data will be used; c) the
influence of stakeholders, including business
groups and advocacy groups for children’s
health, animal welfare, and the environment;
and d) the cultural norms of the jurisdiction
that influence the ethics surrounding animal
use in testing (Garthoff 2005; Schettler 2001;
Spielmann 2003; Zeigler and Stokes 1998). In
the United States, regulatory acceptance is
determined by each individual agency. The
statute that created the ICCVAM specifically
separates validation and regulatory accep-
tance so that an agency may, at its discretion,
accept or reject a validated test (ICCVAM
Authorization Act 2000). It may also take an
intermediate approach and use a validated test
under one or more statutes for some purposes
but not others (ICCVAM 1997). In the
European Union, the journey from validation
to regulatory acceptance appears to be less dis-
jointed and more direct. Member countries
are free to adopt additional procedures for
regulatory acceptance, as are other interna-
tional organizations or programs [OECD;
Registration, Evaluation and Authorization of
Chemicals (REACH); and Science, Children,
Awareness, Legislation, Evaluation (SCALE)]
(Garthoff 2005).
Regulatory acceptance: challenges and
opportunities. To create incentives to develop
alternatives and to maximize the regulatory use
of the information generated by alternative
tests will require that the gap between valida-
tion and regulatory acceptance be narrowed. A
balance must be achieved between the needs of
individual agencies to carry out their statutory
mandates and the societal desire to implement
the 3Rs (refining, reducing, and replacing the
use of animals) while increasing testing of
chemicals for developmental neurotoxic poten-
tial. DNT presents the opportunity to simulta-
neously achieve statutory directives and bring
new alternatives on line, because as discussed
during the TestSmart DNT Workshop, it is
generally acknowledged that current DNT
tests are not adequate for testing large num-
bers of chemicals. Nevertheless, the obstacles
facing new tests in the regulatory area are sub-
stantial. To support alternatives, a more coor-
dinated approach is needed. International
harmonization presents a promising prospect
for both simplifying and accelerating the pace
of regulatory acceptance (Garthoff 2005;
Spielmann 2003). A more integrated process
of acceptance would serve the goals of acceler-
ating the application of new knowledge, pro-
viding transparency for stakeholders and test
developers, and protecting public health as
called for by the statutory mandates that
agencies must meet (Garthoff 2005). 
Workshop Conclusions and
Recommendations
Conclusions. The workshop achieved its pri-
mary objective to bring together the various
stakeholders and individuals from diverse sci-
entific disciplines to examine the TestSmart
DNT goals and to share ideas and concerns
relating to the science and policy of DNT.
The goals of the TestSmart DNT program
were generally supported across all stake-
holder groups, and broad consensus was
reached on the following conclusions: 
1. There is a real and immediate need for an
approach to DNT that incorporates faster
and more efficient and cost-effective tests
for developmental neurotoxicity. The
DNT protocols currently approved for reg-
ulatory decision making are too expensive
in terms of time, resources, and animals to
meet the critical need of evaluating the
thousands of chemicals for which there is
currently little to no DNT information.
2. Short term, the goal is to identify DNT
alternatives with predictive validity that
could be used to prioritize chemicals for
further testing, thereby focusing resources
on exposures most likely to be hazardous to
the developing human nervous system. The
long-term goal is to develop policies that
would incorporate DNT alternatives into
regulatory decision making, which would
significantly reduce, refine, and perhaps
even replace current mammalian in vivo
DNT protocols. 
3. The overall strategy is to focus on DNT
alternatives that assess chemical effects on
evolutionarily conserved neurodevelopmen-
tal events. Coupling the tools and methods
of cell and molecular developmental
neurobiology with high throughput and/or
high content technologies will be necessary
to rapidly expand the DNT database. An
immediate need is to initiate a systematic
evaluation of alternative testing models to
determine their relevance and reliability
for DNT. Such an evaluation would be
enhanced if DNT alternatives were tested
against a generally accepted set of reference
chemicals, which currently does not exist. 
4. The creation of a high-quality open data-
base to catalog existing DNT data and inte-
grate new DNT data as they become
available would significantly expedite the
process of identifying and validating
promising DNT end points and alternative
DNT models. The usefulness of such a
database would be enhanced significantly if
it included access to DNT data generated
by pharmaceutical, chemical, and other
industries as part of their in-house product
safety evaluations. Critical to the success of
the database is identifying resources to sup-
port its creation and maintenance. 
5. To achieve the TestSmart DNT goals it will
be essential to continue to build a working
group of scientists and policy makers who
will maintain the momentum of the first
workshop and interact to develop both the
strategic goals and the process for establish-
ing an alternative DNT testing system with
broad applicability to protective public
health decisions. Thus, as the science devel-
ops, its policy implications will be under-
stood, and as policy needs are articulated,
the science can respond. 
Recommendations. A pressing and imme-
diate problem is the paucity of data regarding
the predictive validity, specificity, and sensi-
tivity of in vitro and alternative systems-based
models for DNT. Such data are required not
only to evaluate any given model, but also to
determine how many end points and/or mod-
els are necessary for predictive validity. Thus,
an immediate need is to begin testing candi-
date models—raising additional questions
regarding which chemicals to use for these
tests. Superimposed on these issues are the
problems of limited resources (how do we pri-
oritize models for testing?) and coordinating
the collection, storage, and analyses of DNT
data. Specific recommendations for questions
to be addressed at the second TestSmart
DNT workshop as they relate to each of the
three overall goals of the TestSmart DNT
program include: 
Develop scientifically valid and efficient
DNT alternatives
1. Develop a structured plan for DNT
data collection and storage 
• Develop a template for an open data-
base that includes relevant fields for
chemical- and end point–specific data
TestSmart DNT workshop
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• Populate database with currently avail-
able DNT data and develop a structure
for integrating evolving DNT data
• Provide open access for all stakeholders 
2. Identify a reference set of chemicals for
evaluating the reliability and relevance
of alternative DNT models 
3. Develop a decision framework for ana-
lyzing data generated using DNT alter-
natives
• Develop criteria for measuring suc-
cess with DNT alternatives
• Integrate information from alterna-
tives with data obtained from mam-
malian in vivo tests
• Apply computational toxicology and
biostatistical approaches to evaluate
the predictive validity of tests and test
batteries 
4. Identify resources to support develop-
ment of DNT alternatives 
Develop policies for incorporating DNT
alternatives into regulatory decision making
1. Streamline the process of validation
2. Narrow the gap between validation and
regulatory acceptance of DNT alternatives
• Develop transparent and scientifically
robust criteria for the acceptance of
validated tests in regulatory decision
making
• Involve regulatory agencies through-
out all stages of test development
• Review guidance and policies to
ensure that these encourage applica-
tion of data generated by alternatives
• Recognize the value of biologic end-
point data and its application to deci-
sion making
3. Harmonize validation and regulatory
acceptance of DNT alternatives 
• Within countries or jurisdictions
sharing common regulatory organiza-
tions, harmonize validation and regu-
latory acceptance
• Between countries and jurisdictions,
establish international principles for
validation and regulatory acceptance
• Employ priority and tiered testing
approaches that incorporate alterna-
tive testing protocols and data where
feasible
Identify opportunities for reducing, refining,
or replacing the use of animals in DNT 
1. Refine current animal testing 
2. Reduce the number of animals used in
existing DNT protocols 
• Apply data from DNT alternatives to
focus testing in mammalian in vivo
protocols to relevant end points 
• Develop a tiered testing approach that
can be used for regulatory decision
making 
• Ensure an international cooperative
effort to streamline and harmonize
the scientific validation of candidate
DNT alternatives
3. Replace animals by validating alterna-
tive methods 
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